neuro-nasal

why it works

The third stack here organised by route rather than by goal, and the reasoning is the same: partial first-pass bypass and a nose-to-brain path along the olfactory and trigeminal nerves.

Intranasal insulin is the best-evidenced item by a wide margin. There are multiple human trials in memory and in Alzheimer's and mild cognitive impairment populations, with mixed but genuine results, which is a great deal more than anything else here has. ⚠️ THE SAFETY LINE IS NOT OPTIONAL: insulin is insulin. Hypoglycaemia is the mechanism-named risk, the intranasal route is chosen specifically to limit systemic exposure rather than to eliminate it, and anyone who is diabetic or on glucose-lowering therapy is in a completely different situation from a healthy reader.

Taltirelin is a TRH analogue with far longer duration than TRH itself and a much better central-to-endocrine ratio, which is the entire point of the molecule. It is approved in Japan for spinocerebellar degeneration, so it has a real regulatory history worth crediting. ⚠️ It is a thyroid-axis compound and its effects on TSH and prolactin are real.

Adamax is an adamantylated analogue in the Semax family, and the adamantane group is there to improve stability and central penetration.

P21 is a peptide fragment derived from ciliary neurotrophic factor, associated with neurogenesis in rodent work. Thin literature, marked optional, and the honest first item to drop.

how they work together

⚠️ THESE ARE FOUR DIFFERENT LEVERS ON ONE TARGET, NOT FOUR COMPOUNDS ACTING ON ONE PATHWAY, and that breadth is both the rationale and the reason the net effect is hard to predict.

Intranasal insulin is metabolic: it acts on brain insulin signalling, which regulates glucose utilisation in neurons and has documented effects on memory in human trials. Taltirelin is neuroendocrine, a thyrotropin-releasing hormone analogue whose central effects include arousal and cholinergic activation. Adamax is melanocortin-adjacent through the Semax lineage. P21 is neurotrophic.

Four separate systems, one route, one goal. That is a defensible structure and it is also the honest reason nobody can say what running all four together produces: there is no shared mechanism to reason forward from, and no study of the combination.

The route itself is the genuine common factor, and it is worth being exact about how well each item earns it. Intranasal insulin simply is the route; it is what the human trials used and there is no other sensible way to give it for this purpose. Adamax was sold as a nasal spray by the one outfit that made it, although no study of Adamax by any route has ever been published.

⚠️ TALTIRELIN IS THE ODD ONE OUT, AND IN THE OPPOSITE DIRECTION FROM THE USUAL COMPLAINT. A PubMed sweep across the peptide catalogue found no study giving taltirelin nasally in any species, and the reason is not neglect: it was engineered to be orally active and to survive the gut, which is the whole advantage it has over the TRH it derives from. The nasal route is not getting taltirelin past a barrier, because taltirelin does not have that barrier. It sits here on the goal rather than on the route, which makes this a delivery grouping with one member that does not need the delivery.

what it feels like

Intranasal insulin is the only item with substantial human data on what it does, and in those trials the effect is on memory measures rather than on how people feel; it is largely imperceptible in the moment.

Taltirelin is the most likely to be noticed, with reported arousal and alertness effects, and it is also the one whose endocrine effects are real.

Adamax and P21 are quiet. As with any intranasal peptide, onset by route is fast and that speed says nothing about whether the compound is doing what is hoped.